Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
DLBCL: early-phase trial registry
8 of 15 indexed DLBCL trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · 8 currently recruiting · #1,140 of 28,707 conditions by registered trial count
DLBCL: 15 US clinical trials tracked, 8 recruiting.
DLBCL is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is University of Rochester, running 2 of these trials.
Enrollment posture brief
Registry condition dlbcl
OPEN 8 | RECR 53% | LATE 0 | EARLY 15 | RANK #1140 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Beta-Thalassemia (53% recruiting · 15 trials)
DLBCL lists 8 open slots (53% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for DLBCL on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
DLBCL is recruiting above its size-band peers.
8 of 15 indexed trials (53.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of DLBCL trials is spread across many organizations.
University of Rochester accounts for 2 of 15 trials (13.3%). 14 distinct sponsors appear on at least one study for this condition label.
-
Most DLBCL trials plan to enrol fewer than 100 people.
Median target enrolment is 42 among the 15 trials that report a genuine target (sentinel values excluded). 10 of those (66.7%) plan for fewer than 100 participants.
-
DLBCL research is mostly interventional.
15 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
15 total, page 1 of 1
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Merck Sharp & Dohme
NCT05139017
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
National Cancer Institute (NCI)
NCT04002947
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
Poseida Therapeutics
NCT06014762
Study of SGR-1505 in Mature B-Cell Neoplasms
Schrödinger
NCT05544019
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
Acepodia Biotech
NCT05653271
A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
University of Rochester
NCT03758989
A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
Ranok Therapeutics (Hangzhou) Co.
NCT05487170
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
Memorial Sloan Kettering Cancer Center
NCT04512716
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
Genmab
NCT03625037
Study of Oral MRT-2359 in Selected Cancer Patients
Monte Rosa Therapeutics
NCT05546268
A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL
University of Rochester
NCT04594798
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
Bio-Path Holdings
NCT04072458
Split-Dose R-CHOP for Older Adults With DLBCL
University of Wisconsin, Madison
NCT03943901
Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies
Stanford University
NCT04088890
Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL
Kymera Therapeutics
NCT05233033
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 10 |
| Phase 2 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on DLBCL records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on DLBCL trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this DLBCL page
15 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 DLBCL trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Rochester sponsors the most DLBCL trials on record, review their full trial history before evaluating a specific study. See University of Rochester's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This DLBCL condition card totals 15 registered trials; most-linked intervention Cyclophosphamide; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.